Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3

Area of Science:

• Molecular Biology
• Cancer Genetics
• Pharmacology

Background:

• Gene alterations are a known cause of drug resistance in acute leukemia.
• Understanding these resistance mechanisms is crucial for developing effective chemotherapy strategies.

Purpose of the Study:

• To investigate the genetic mechanisms of idarubicin resistance in the human acute leukemia cell line MOLT-3/IDR compared to its sensitive counterpart MOLT-3.
• To identify specific genetic differences, including mutations in mitochondrial and nuclear DNA, associated with drug resistance.

Main Methods:

• Complete mitochondrial and nuclear DNA analyses were performed on MOLT-3 and MOLT-3/IDR cell lines.
• Comparative Genomic Hybridization (CGH) array analysis was used to identify genetic alterations.
• Gene sequencing and real-time PCR were employed to analyze specific gene mutations and expression levels.
• Protein structure prediction was utilized to assess the impact of identified mutations.

Main Results:

• A unique mutation (p.Thr61Ile) in the ND3 gene of mitochondrial DNA was identified in MOLT-3/IDR cells.
• A mutation (G1716K) within the stop codon of the GALNT2 gene was found in MOLT-3/IDR cells, leading to an extended protein.
• The GALNT2 gene showed a specific expression value (0.35) in the resistant cells.
• Protein structure prediction indicated a structural change in GALNT2 in MOLT-3/IDR cells.

Conclusions:

• Specific genetic alterations in both mitochondrial (ND3) and nuclear (GALNT2) DNA distinguish idarubicin-resistant leukemia cells from sensitive ones.
• The identified GALNT2 mutation, resulting in protein elongation and structural changes, is a potential contributor to idarubicin resistance in acute leukemia.